Ultragenyx sells second priority review voucher as Biomea shares tumble after oral GLP-1 data
read at Endpoints ↗DealNeutral
Ultragenyx Pharmaceutical, a commercial-stage rare disease company, completed its second sale of a priority review voucher this month.
The voucher sale reflects the company's strategy of monetizing regulatory incentives earned from previous approvals.
In separate news, Biomea Sciences saw its stock decline after releasing data on its oral GLP-1 program, which investors interpreted negatively.
The brief also noted updates from United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics, though no details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump”
read at Endpoints ↗83 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that